The startup develops drugs that enhance pyroptosis, a form of programmed cell death, to trigger robust immune responses against tumors. This approach targets inflammation and tumor eradication, providing a novel therapeutic strategy for difficult-to-treat cancers.
Funding
Funding not disclosed
BMFounders
Product
Problem
Many cancers are difficult to treat due to their resistance to existing therapies and their ability to evade the immune system. Current cancer treatments often fail to elicit a strong and durable immune response, leading to recurrence and metastasis. New therapeutic strategies are needed to overcome these limitations and effectively eradicate tumors.
Solution
The startup is developing a novel class of drugs that harness pyroptosis, a form of programmed cell death, to stimulate potent anti-tumor immune responses. By precisely inducing pyroptosis in cancer cells, the drugs trigger the release of inflammatory signals that alert and activate the immune system. This approach aims to convert immunologically "cold" tumors into "hot" tumors, making them more susceptible to immune-mediated destruction. The resulting inflammation promotes the infiltration of immune cells into the tumor microenvironment, leading to tumor eradication and long-term immunity.
Target Audience
The primary target audience includes pharmaceutical companies, oncologists, and patients with difficult-to-treat cancers who are seeking innovative therapeutic options.
Features
- Small-molecule drugs designed to selectively induce pyroptosis in cancer cells
- Targeted activation of the innate immune system to enhance anti-tumor immunity
- Modulation of the tumor microenvironment to promote immune cell infiltration
- Potential for combination therapy with existing immunotherapies and chemotherapies
- Preclinical data demonstrating efficacy in various cancer models